Cia Paranaense De Energia Bolsa (NYSE: ELPC)

Últimas noticias sobre Cia Paranaense De Energia (NYSE:ELPC) Bolsa

Cia Paranaense De Energia

Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.

Companhia Paranaense de Energia (COPEL) American Depositary Shares (each representing four (4) Common Shares)

Cia Paranaense De Energia Copel

WIIM

Opus Genetics shares are trading higher after the company announced its LYNX-2 Phase 3 trial met its primary endpoint.

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Shares of Science Applications International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) fell sharply in today's pre-market trading after the company reported<a href="https://www.benzinga.com/quote/SAIC"> first-quarter results</a>.
Science Applications Intl posted adjusted earnings of $1.92 per share, missing market estimates of $2.22 per share. The company posted quarterly sales of $1.88 billion versus expectations of $1.87 billion.
SAIC shares dipped 6.5% to $108.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) declined 18.4% to $62.60 in pre-market trading after the company filed for mixed shelf offering.</li>
<li>ContextLogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares tumbled 18.3% to $6.70 in pre-market trading. ContextLogic will commence trading on the OTC Markets and delist from the Nasdaq.</li>
<li>Lucid Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 15.1% to $1.18 in pre-market trading. Lucid Diagnostics may offer sell shares of common stock of up to $25 million.</li>
<li>Algoma Steel Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) fell 9.2% to $4.78 in pre-market trading.</li>
<li>LiveWire Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NASDAQ">LVWR</a>) dipped 8.7% to $4.10 in pre-market trading.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) fell 7.3% to $3.07 in pre-market trading.</li>
<li>Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) fell 6.9% to $6.70 in pre-market trading. Arvinas and Pfizer&#8217;s Vepdegestrant demonstrated statistically significant 2.9-month PFS benefit over Fulvestrant in ESR1-mutant second-line advanced breast cancer.</li>
<li>Qudian Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QD#NYSE">QD</a>) fell 6.4% to $2.77 in pre-market trading. Qudian reported first quarter unaudited financial results on Friday.</li>
<li>IperionX Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPX#NASDAQ">IPX</a>) fell 5.5% to $22.86 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 1.5% to $341.25 in pre-market trading. Tesla experienced a decline in sales in China compared to rivals like Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) and BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>), which posted strong growth in May.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shuttestock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARVN

ASTL

BYDDF

BYDDY

LOGC

LUCD

LVWR

SAIC

SBET

TSLA

XPEV

SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the communication services sector.
<h3 class="wp-block-heading">Nexstar Media Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.37%</li>
<li>Benchmark analyst Daniel Kurnos maintained a Buy rating and increased the price target from $215 to $220 on May 9, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Steven Cahall maintained an Overweight rating and slashed the price target from $216 to $200 on May 1, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On May 8, Nexstar Media Group reported better-than-expected first-quarter EPS results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602">NXST news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602"><img loading="lazy" decoding="async" width="920" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02083756/image-6.png" alt="" class="wp-image-935136" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02083756/image-6.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02083756/image-6-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02083756/image-6-768x701.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Omnicom Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.81%</li>
<li>JP Morgan analyst David Karnovsky maintained an Overweight rating and cut the price target from $116 to $104 on April 16, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Wells Fargo analyst Steven Cahall maintained an Equal-Weight rating and cut the price target from $99 to $84 on April 16, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On April 15, Omnicom Group reported worse-than-expected first-quarter revenue results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602">OMC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602"><img loading="lazy" decoding="async" width="873" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02083849/image-1-1.png" alt="" class="wp-image-935138" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02083849/image-1-1.png 873w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02083849/image-1-1-300x287.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02083849/image-1-1-768x735.png 768w" sizes="(max-width: 873px) 100vw, 873px" /></a></figure>
<h3 class="wp-block-heading">AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.99%</li>
<li>Tigress Financial analyst Ivan Feinseth maintained a Buy rating and raised the price target from $32 to $34 on April 29, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Morgan Stanley analyst Simon Flannery maintained an Overweight rating and increased the price target from $30 to $31 on April 24, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: AT&amp;T will release second-quarter earnings on July 23.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest T <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602"><img loading="lazy" decoding="async" width="925" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02084009/image-7.png" alt="" class="wp-image-935141" style="width:610px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02084009/image-7.png 925w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02084009/image-7-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02084009/image-7-768x703.png 768w" sizes="(max-width: 925px) 100vw, 925px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Dividends

Price Target

Analyst Ratings

NXST

Wall Street's Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields

SharpLink Gaming shares are trading lower after the company announced a mixed-shelf offering

Citigroup analyst Matthew Herrmann initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Buy rating and announces Price Target of $43.

Initiation

Citigroup Initiates Coverage On Aspen Insurance Hldgs with Buy Rating, Announces Price Target of $43

April&#8217;s Personal Consumption Expenditures data presented a complex picture for Jerome Powell, with economists suggesting the persistent cloud of tariff uncertainty compels the central bank to &#8220;wait and see&#8221; policy stance even as &#8220;disinflation&#8221; has set in.
What Happened: The April PCE report, the Federal Reserve&#8217;s preferred inflation gauge, revealed a deceleration in headline inflation to 2.1% annually, marking the lowest print for the year so far. Core PCE, excluding volatile food and energy prices, also eased to 2.5% from a revised 2.7% in March.
This data confirms a trend of &#8220;continued disinflation,&#8221; a point highlighted by Jamie Cox, the managing partner for Harris Financial Group, who remarked, &#8220;This PCE report confirms continued disinflation, despite the refrain from everyone that disinflation isn't possible in this environment. As Alan Greenspan would have said, it's a conundrum.&#8221;
Despite this positive development, the broader economic landscape is clouded with uncertainty, primarily due to tariff turmoil, which has now entered the courts.
Jeffrey Roach, the chief economist for LPL Financial, noted that while the stable job market, evidenced by a rise in the savings rate to a one-year high of 4.9% and robust real disposable personal income growth of 0.7%, provides support for households, the fluid tariff policy poses an &#8220;upside risk to inflation.&#8221;
He stated, &#8220;As long as the job market remains stable, the Fed has the luxury of remaining in &#8216;wait and see&#8217; mode. We think there is upside risk to inflation as many baseline forecasts cannot reasonably account for the fluid tariff policy.&#8221;
This sentiment was also echoed by Chris Zaccarelli, CIO at Northlight Asset Management. Zaccarelli suggests that the Fed&#8217;s relative silence this year is a result of a lack of significant inflation or unemployment surprises, allowing them to keep rates unchanged.
However, he warns that &#8220;At some point, the tariff uncertainty has to be addressed.&#8221; He points out that if clarity on tariffs isn&#8217;t achieved quickly, and the economy begins to stall, the Fed might be forced into aggressive rate cuts – a scenario he cautions against for those hoping for immediate easing.
See Also: <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45716143/trump-administration-set-to-ease-big-bank-rules-in-major-rollback-since-2008-crisis-here-are-the-stocks-and-etfs-investors-could-consider">Trump Administration Set To Ease Big Bank Rules In Major Rollback Since 2008 Crisis: Here Are The Stocks And ETFs Investors Could Consider</a>
Why It Matters: The core of the &#8220;puzzle&#8221; lies in the interplay of these factors: seemingly benign inflation and a stable job market that would typically allow for patience from the Fed, versus the unpredictable impact of tariffs, which could be inflationary in nature.
Meanwhile, the Federal appeals court <a href="https://www.benzinga.com/news/legal/25/05/45683326/trump-tariffs-temporarily-preserved-as-appeals-court-pauses-lower-ruling">lifted a temporary pause</a> on Donald Trump&#8216;s tariffs, which were earlier invalidated by the Court of International Trade.
This, as China violated the trade terms, as highlighted by Trump in a Truth Social <a href="https://truthsocial.com/@realDonaldTrump/posts/114596705340367716">post</a> and echoed by Treasury Secretary Scott Bessent, who clarified that China was withholding critical minerals it agreed to release in a trade deal the country signed with U.S. negotiators last month in Geneva.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 0.33% at $587.47, while the QQQ declined 0.42% to $516.95, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45715677/tom-lee-bets-on-a-new-bull-market-as-trumps-tariff-retreat-fuels-taco-trade-a">Tom Lee Bets On &#8216;A New Bull Market,&#8217; As Trump&#8217;s Tariff Retreat Fuels &#8216;TACO&#8217; Trade Amid &#8216;Run It Hot&#8217; Optimism</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: RozenskiP / Shutterstock.com

Federal Reserve's Preferred Inflation Gauge Falls To 2025 Low, But Jerome Powell Maintains 'Wait-And-See' Stance Amid Tariff Uncertainty

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $958 to $755.

REGN

Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $755

<ul>
<li>Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets</li>
<li>Leadership team realigned in order to enable execution of ancillary protein strategy</li>
<li>Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad &nbsp;</li>
</ul>
JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutrition, and industrial markets. Dyadic's Board of Directors, which has overseen and endorsed this strategy, has appointed Joe Hazelton as President, effective immediately. Mr. Hazelton will also continue in his role as Chief Operating Officer.
Over the past 18 months, Dyadic has made a deliberate pivot to prioritize near-term commercialization opportunities in high-growth, high-value segments such as cell culture media, DNA/RNA technologies, and non-animal food and nutrition ingredients. This pivot has achieved commercial validation through the consummation of high value transactions in the ancillary protein space, including a develop-and-commercialize partnership with Proliant Health and Biologicals for recombinant human albumin, a collaboration with a non-animal dairy enzyme company, and a joint venture with Fermbox Bio that led to the launch of EN3ZYME, recently resulting in a significant purchase order in the cellulosic enzyme market.

Management

DYAI

Dyadic International Announces COO Joe Hazelton Appointed As President, Effective Immediately

NTRB

Nutriband shares are trading higher after the company reported Q1 financial results and beat its Q1 EPS estimate.

This acquisition was primarily acquired from Crypto.com Exchange, Crypto.com's institutional-grade offering. As of June 2, 2025, BTCS holds approximately 13,500 ETH, up from 9,063 ETH at the end of Q1 2025-an increase of approximately 50%.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

BTCS

BTCS Acquires 1,000 ETH For ~$2.63M

Xilio Therapeutics shares are trading lower after the company announced it commenced a public offering of pre-funded warrants.

SABR

Sabre Agrees With Salamair, Utilizing Sabre's Marketplace To Enhance Salamair's Global Visibility, Expand Market Reach, And Drive Revenue Growth

CLEU

China Liberal Education shares are trading lower after the company announced it will be suspended from Nasdaq for failing to address a 20-F delinquency filing.

NIVF

NewGen To Invest  $30M In Solana Digital Asset Staking

Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) ("Safe &amp; Green Holdings" or the "Company"), a leading designer and fabricator of modular structures, and a developer of diversified platforms that advance critical infrastructure through sustainable innovation, announces the signing of a non-binding Letter of Intent ("LOI") to acquire Giant Containers Inc., a recognized leader in modular, container-based infrastructure solutions.
Under the terms of the LOI, Safe &amp; Green will acquire 100% of the issued and outstanding shares of Giant Containers. The transaction also includes the appointment of Giant's CEO, Daniel Kroft, as Vice President of Business Development at Safe &amp; Green.
The proposed acquisition remains subject to customary conditions, including satisfactory due diligence, final negotiation and execution of definitive agreements, board approvals, and any necessary regulatory approvals. Final terms in the definitive agreements are subject to change from the LOI, closing is anticipated on or before June 15, 2025.

SGBX

Safe & Green To Acquire 100% Of Issued And Outstanding Shares Of Giant Containers; Terms Not Disclosed

PSTV

PLUS Therapeutics shares are trading higher. The company reported Q1 financial results.

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Seacoast Banking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBCF#NASDAQ">SBCF</a>) with a Outperform and raises the price target from $31 to $32.

SBCF

Keefe, Bruyette & Woods Maintains Outperform on Seacoast Banking, Raises Price Target to $32

Guidance

The Campbell's Sees FY25 Adjusted EPS To Be At The Low End Of The Guidance Range Due To The Slower Than Anticipated Recovery In The Snacks Business, Excluding The Impact Of Tariffs

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
&#8220;The FDA approval of our third product, mNEXSPIKE&#8230;,&#8221; said Stéphane Bancel, Chief <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/ac45708511/moderna-receives-u-s-fda-approval-for-covid-19-vaccine-mnexspike" rel="noreferrer noopener">Executive Officer of Moderna</a>.
The FDA&#8217;s approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 trial, which enrolled approximately 11,400 participants aged 12 years and older.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
The primary efficacy objective was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNexspike compared to that after the comparator vaccine, mRNA-1273 (Spikevax), Moderna&#8217;s original COVID-19 vaccine.
Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273.
mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.
In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions.
The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.
Moderna expects to have mNexspike available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA, the company&#8217;s approved respiratory syncytial virus (RSV) vaccine.
William Blair writes, &#8220;Approval of mRNA-1283 is an incremental win for Moderna, especially considering HHS Secretary Robert F. Kennedy Jr.&#8217;s negative public opinion on mRNA COVID-19 vaccines, and we continue to see autonomy and data-driven decisions at the FDA.&#8221;
&#8220;We do not see approval of mRNA-1283 as a massive boost to Moderna&#8217;s COVID-19 vaccine sales, which we believe are primarily driven by sentiment surrounding the vaccination market in general, but this is a critical step in the regulatory path for the combo flu/COVID vaccine product, mRNA-1083, which uses mRNA-1283 as the COVID-19 component of its formulation,&#8221; analyst Myles Minter writes.
Analyst Minter says Moderna is still facing challenges from new government policies, including <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45663794/hhs-cancels-590m-moderna-bird-flu-vaccine-deal-casting-uncertainty-over-pandemic-preparedness-effort" rel="noreferrer noopener">losing about $700 million</a> in funding from the Department of Health and Human Services for its bird flu vaccine project.
In addition, William Blair writes that the company&#8217;s goal to break even by 2028 is overly optimistic since it would need to more than double its revenue—based on cash costs—to reach that target.
In May, the FDA approved Novavax, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) Nuvaxovid for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g. asthma, cancer, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45489838/u-s-fda-approves-bla-for-novavaxs-covid-19-vaccine" rel="noreferrer noopener">diabetes, obesity, smoking)</a>.
Achievement of the U.S. license approval has triggered a&nbsp;$175 million&nbsp;milestone payment from Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Price Action: MRNA stock is up 4.82% at $27.84 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/05/45703385/dell-wins-wall-street-praise-after-12-billion-ai-server-orders-solid-commercial-pc-demand" target="_blank" rel="noreferrer noopener">Dell Wins Wall Street Praise After $12 Billion AI Server Orders, Solid Commercial PC Demand</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Biotech

Large Cap

Health Care

General

MRNA

NVAX

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals

Citigroup analyst Patrick Cunningham initiates coverage on RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Buy rating and announces Price Target of $135.

Citigroup Initiates Coverage On RPM Intl with Buy Rating, Announces Price Target of $135

ALLETE

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas

Comp En De Mn Cemig ADS American Depositary Receipts

Centrais Electricas Brasileiras S A American Depositary Shares (Each representing one Common Share)

Centrais Eletricas

Centrais Electricas Brasileiras S.A. Sponsored ADS representing Pfd Shares

Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor) American Depositary Shares

Empresa Distribuidora y

Edison Intl

Companhia Paranaense de Energia (COPEL) American Depositary Shares (each representing one Unit consisting one Common Share and four non-voting Class B Preferred Shares)

Enel Chile S.A. American Depositary Shares (Each representing 50 shares of Common Stock)

Comments

Cia Paranaense De Energia

Noticias

Últimas noticias sobre Cia Paranaense De Energia (NYSE:ELPC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL